Inovio Pharmaceuticals
115 hedge funds and large institutions have $168M invested in Inovio Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 33 reducing their positions, and 25 closing their positions.
38% more call options, than puts
Call options by funds: $4.75M | Put options by funds: $3.45M
12% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 33
8% more capital invested
Capital invested by funds: $156M → $168M (+$12M)
0.45% less ownership
Funds ownership: 3.21% → 2.76% (-0.45%)
7% less funds holding
Funds holding: 123 → 115 (-8)
24% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Dialectic Capital Management
Norwalk,
Connecticut
|
+$1.61M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.27M |
| 3 |
RFC
Russell Frank Company
Seattle,
Washington
|
+$1.07M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$712K |
| 5 |
GC
Globeflex Capital
San Diego,
California
|
+$646K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$4.16M |
| 2 |
Millennium Management
New York
|
-$3.88M |
| 3 |
Renaissance Technologies
New York
|
-$2.64M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.39M |
| 5 |
IG
ING Group
Amsterdam,
Netherlands
|
-$2.25M |
INO Hedge Fund Activity: Q1 2016 in Review
115 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2016, worth a combined $168M — up 7.7% from $156M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of INO and 19 opened new positions — a net loss of 6 holders — while 33 trimmed existing stakes and 37 added.
The largest buyer was Dialectic Capital Management, opening a new position worth an estimated $1.61M. The largest seller was Sabby Management, exiting entirely with an estimated $4.16M sold.
- 115 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2016, down from 123 in Q4 2015.
- Funds reported $168M of Inovio Pharmaceuticals stock for Q1 2016, up 7.7% quarter-over-quarter.
- 19 funds opened new Inovio Pharmaceuticals positions in Q1 2016 and 25 closed out, a net change of -6 holders.
- The largest Inovio Pharmaceuticals buyer in Q1 2016 was Dialectic Capital Management, an estimated $1.61M added.
- The largest Inovio Pharmaceuticals seller in Q1 2016 was Sabby Management, an estimated $4.16M sold.
Based on aggregated 13F filings for Q1 2016.